Back to top
more

Dova Pharmaceuticals, Inc. (DOVA)

(Delayed Data from NSDQ)

$9.62 USD

9.62
129,426

+0.18 (1.91%)

Updated May 3, 2019 04:00 PM ET

After-Market: $9.64 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Will Dova Pharmaceuticals (DOVA) Report Negative Q3 Earnings? What You Should Know

Dova Pharmaceuticals (DOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?

Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%

Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher

Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.

Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

Dova Receives Approval for Doptelet in Europe, Stock Up

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Implied Volatility Surging for Dova Pharmaceuticals (DOVA) Stock Options

Investors need to pay close attention to Dova Pharmaceuticals (DOVA) stock based on the movements in the options market lately.

Dova Pharmaceuticals (DOVA) Reports Q1 Loss, Tops Revenue Estimates

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of 14.71% and 15.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Dova (DOVA) Stock?

Investors need to pay close attention to Dova (DOVA) stock based on the movements in the options market lately.

Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings

Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.

Dova Pharmaceuticals (DOVA) Reports Q3 Loss, Tops Revenue Estimates

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of 15.85% and 10.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?